10x Genomics Inc to Present at J.P. Morgan Healthcare Conference
| TXG Stock | USD 16.16 1.08 7.16% |
Roughly 55% of 10X Genomics' stockholders are presently thinking to get in. The analysis of overall sentiment of trading 10X Genomics stock suggests that some investors are interested at this time. The current market sentiment, together with 10X Genomics' historical and current headlines, can help investors time the market. In addition, many technical investors use 10X Genomics stock news signals to limit their universe of possible portfolio assets.
10X |
Summary 10x Genomics Inc , a prominent player in the field of single cell and spatial biology, announced on January 2, 2025, that its management team will
Read at gurufocus.com
 |
10X Genomics Fundamental Analysis
We analyze 10X Genomics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of 10X Genomics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of 10X Genomics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
EBITDA
EBITDA Comparative Analysis
10X Genomics is currently under evaluation in ebitda category among its peers. EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.
10X Genomics Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with 10X Genomics stock to make a market-neutral strategy. Peer analysis of 10X Genomics could also be used in its relative valuation, which is a method of valuing 10X Genomics by comparing valuation metrics with similar companies.
Peers
10X Genomics Related Equities
| BEAM | Beam Therapeutics | 4.65 | ||||
| TWST | Twist Bioscience | 3.68 | ||||
| FATE | Fate Therapeutics | 1.60 | ||||
| VCYT | Veracyte | 1.27 | ||||
| GH | Guardant Health | 1.74 |
Complementary Tools for 10X Stock analysis
When running 10X Genomics' price analysis, check to measure 10X Genomics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy 10X Genomics is operating at the current time. Most of 10X Genomics' value examination focuses on studying past and present price action to predict the probability of 10X Genomics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move 10X Genomics' price. Additionally, you may evaluate how the addition of 10X Genomics to your portfolios can decrease your overall portfolio volatility.
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data |